FOLD - Amicus Therapeutics: Too Cheap At Under $10 A Share

2024-05-20 05:06:00 ET

Summary

• Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth.
• The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction.
• Analyst firms are also largely positive on the company's prospects.
• An analysis of Amicus Therapeutics is presented in the paragraphs below.

Today, we put rare disease concern Amicus Therapeutics ( FOLD ) under the spotlight. The shares have recently slid under the $10 a share level, which seems too cheap given the company's revenue growth and movement towards profitability. We dig into recent quarterly results and update our investment analysis on this small-cap name in the paragraphs below....

For further details see: